United Therapeutics CEO Exercises Options and Sells $5.58M in Shares Under 10b5-1 Plan

Executive Summary

On October 27, 2026, Dr. Martine A. Rothblatt, Chairperson & CEO of United Therapeutics Corp ($UTHR), executed an option exercise and corresponding sale of 9,500 shares of common stock. The transactions were carried out pursuant to a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025.

Transaction Details

• Option Exercise: 9,500 stock options with an exercise price of $117.76 (expiring March 15, 2027) were exercised.
• Open Market Sales: 9,500 shares were sold across 11 tranches at weighted average prices ranging from $582.66 to $592.84, generating gross proceeds of approximately $5.58 million (~$587.73 per share average).
• Net Profit Spread: Realized pre-tax gain of approximately $4.46 million.
• Ownership Structure: The options and resulting common shares were held indirectly via family trusts.

Holdings Context

Following the transactions, Dr. Rothblatt continues to hold significant beneficial ownership:

• 324,443 shares held indirectly via the primary family trust.
• 40,513 shares held directly.
• Additional shares held across multiple other family trusts and spouse accounts (~303,772 shares).
• 147,910 derivative stock options remaining in the family trust.

Market & Significance Assessment

• Significance Level: Low.
• Analysis: This transaction represents standard executive compensation realization via an automated Rule 10b5-1 trading plan. Because the options expire in March 2027 and the sales were scheduled under a plan adopted in late 2025, this does not indicate an opportunistic market view or a change in sentiment.